Carlisle Cos. (CSL)
367.14
0.00 (0.00%)
Upcoming Events
Latest Headlines
Carlisle Cos. (CSL) to Acquire MTL Holdings
March 18, 2024 6:54 PM - StreetInsider
Carlisle Companies to Acquire MTL Holdings, a Leader in Edge Metal and Non-Insulated Architectural Wall Systems
March 18, 2024 6:47 PM - BizWire
Carlisle Cos. (CSL) Files Mixed Shelf
March 15, 2024 4:23 PM - StreetInsider
Form S-3ASR CARLISLE COMPANIES INC
March 15, 2024 4:22 PM - SEC Filing
Form SC 13G/A CARLISLE COMPANIES INC Filed by: BlackRock Inc.
March 7, 2024 12:30 PM - SEC Filing
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
March 6, 2024 9:01 AM - PR NewsWire
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: OSTRANDER GREGG A
March 5, 2024 2:01 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Singh Jesse G
March 5, 2024 1:59 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Ricard Corrine D.
March 5, 2024 1:55 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: BOHN ROBERT G
March 5, 2024 1:50 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: ADAMS ROBIN J
March 5, 2024 1:47 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Collins Jonathan R.
March 5, 2024 1:42 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Frias James D
March 5, 2024 1:40 PM - SEC Filing
Form PRE 14A CARLISLE COMPANIES INC For: May 01
March 1, 2024 5:25 PM - SEC Filing
Travere Therapeutics (TVTX) and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024 7:06 AM - StreetInsider
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024 7:05 AM - Globe NewsWire
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
February 23, 2024 2:00 AM - PR NewsWire
Form 4 CARLISLE COMPANIES INC For: Feb 21 Filed by: KOCH D CHRISTIAN
February 22, 2024 4:22 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 15 Filed by: KOCH D CHRISTIAN
February 20, 2024 1:20 PM - SEC Filing
Form 10-K CARLISLE COMPANIES INC For: Dec 31
February 16, 2024 2:08 PM - SEC Filing
Form SC 13G/A CARLISLE COMPANIES INC Filed by: VANGUARD GROUP INC
February 13, 2024 5:03 PM - SEC Filing
Form 144 CARLISLE COMPANIES INC Filed by: KOCH D CHRISTIAN
February 13, 2024 1:15 PM - SEC Filing
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
February 12, 2024 10:54 PM - PR NewsWire
Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Snyder Lori A
February 12, 2024 2:45 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Schwar Stephen
February 12, 2024 2:05 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: SMITH DAVID W
February 12, 2024 1:51 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Selbach Scott C
February 12, 2024 1:41 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Berlin John E
February 12, 2024 1:12 PM - SEC Filing
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
February 11, 2024 5:47 PM - PR NewsWire
Form 144 CARLISLE COMPANIES INC Filed by: Snyder Lori A
February 8, 2024 4:24 PM - SEC Filing
Form 144 CARLISLE COMPANIES INC Filed by: Snyder Lori A
February 8, 2024 4:10 PM - SEC Filing
Form 144 CARLISLE COMPANIES INC Filed by: Schwar Stephen
February 8, 2024 3:56 PM - SEC Filing
Form 144 CARLISLE COMPANIES INC Filed by: Berlin John E
February 8, 2024 3:11 PM - SEC Filing
Form 144 CARLISLE COMPANIES INC Filed by: SMITH DAVID W
February 8, 2024 2:59 PM - SEC Filing
Form 144 CARLISLE COMPANIES INC Filed by: Selbach Scott C
February 8, 2024 11:50 AM - SEC Filing
Carlisle (CSL) PT Raised to $355 at Oppenheimer
February 7, 2024 7:39 AM - StreetInsider
Carlisle (CSL) PT Raised to $365 at Baird
February 7, 2024 6:57 AM - StreetInsider
Carlisle Cos. (CSL) Tops Q4 EPS by 68c
February 6, 2024 4:14 PM - StreetInsider
Form 8-K CARLISLE COMPANIES INC For: Feb 06
February 6, 2024 4:12 PM - SEC Filing
Carlisle Companies Reports Fourth Quarter Results
February 6, 2024 4:05 PM - BizWire
Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: SMITH DAVID W
February 5, 2024 5:25 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: ALDRICH STEPHEN
February 5, 2024 5:16 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: Zdimal Kevin P
February 5, 2024 5:05 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: Snyder Lori A
February 5, 2024 4:58 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: Selbach Scott C
February 5, 2024 4:51 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: Schwar Stephen
February 5, 2024 4:45 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: KOCH D CHRISTIAN
February 5, 2024 4:36 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Feb 02 Filed by: Berlin John E
February 5, 2024 4:27 PM - SEC Filing
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
February 5, 2024 8:30 AM - BizWire
Carlisle Receives First-Ever LEED Platinum v4 Certification in North America
February 1, 2024 3:15 PM - BizWire
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: OSTRANDER GREGG A
January 31, 2024 2:58 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: BOHN ROBERT G
January 31, 2024 2:48 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: Berlin John E
January 31, 2024 2:38 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: READY FRANK J.
January 31, 2024 2:29 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: Schwar Stephen
January 31, 2024 2:24 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: PATEL MEHUL
January 31, 2024 2:04 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: SMITH DAVID W
January 31, 2024 1:55 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: ALDRICH STEPHEN
January 31, 2024 1:35 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: Snyder Lori A
January 31, 2024 1:17 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: Zdimal Kevin P
January 31, 2024 12:56 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: Selbach Scott C
January 31, 2024 12:36 PM - SEC Filing
Form 4 CARLISLE COMPANIES INC For: Jan 30 Filed by: KOCH D CHRISTIAN
January 31, 2024 12:28 PM - SEC Filing
Carlisle Cos. (CSL) Declares $0.85 Quarterly Dividend; 1.1% Yield
January 30, 2024 4:06 PM - StreetInsider
Carlisle Companies Declares Regular Quarterly Dividend
January 30, 2024 4:05 PM - BizWire
Form 8-K CARLISLE COMPANIES INC For: Jan 30
January 30, 2024 4:03 PM - SEC Filing
Amphenol (APH) to Acquire CIT Business From Carlisle (CSL) for $2.025B Cash
January 30, 2024 8:01 AM - StreetInsider
Carlisle Companies Signs Definitive Agreement to Sell Carlisle Interconnect Technologies to Complete its Pivot to a Pure Play Building Products Company
January 30, 2024 8:00 AM - BizWire
Amphenol Corporation to Acquire CIT Business From Carlisle
January 30, 2024 8:00 AM - BizWire
Form SC 13G/A CARLISLE COMPANIES INC Filed by: BlackRock Inc.
January 24, 2024 2:28 PM - SEC Filing
Carlisle Companies to Announce Fourth Quarter 2023 Results on February 6, 2024
January 23, 2024 4:05 PM - BizWire
Carlisle (CSL) PT Raised to $354 at Baird
January 17, 2024 6:21 AM - StreetInsider
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
January 16, 2024 8:00 AM - PR NewsWire
CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
January 3, 2024 8:00 AM - PR NewsWire
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials
January 2, 2024 8:00 AM - PR NewsWire
Carlisle (CSL) PT Raised to $345 at Oppenheimer
January 2, 2024 7:28 AM - StreetInsider
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
December 21, 2023 8:01 AM - PR NewsWire
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
December 21, 2023 8:00 AM - BizWire
Full Article List